May. 27 at 1:49 PM
Wedbush⬆️
$APGE's to
$135 (was
$120) and reiterated at Outperform.
$REGN - SNY
$LLY KYMR CRVS NKTR
Wedbush: APGE reported APEX Part B Phase 2 data that beat historical efficacy reported for Dupixent and Eblyss.
At the mid-dose that will be used as the Phase 3 dose, induction EASI-75 and IGA 0/1 surpassed those benchmarks set by Dupixent and Ebglyss, with responses possibly deepening beyond 16 weeks.
APGE will begin a registrational Phase 3 program in the second half of 2026, consisting of two replicate monotherapy studies and one steroid combination study—APGE expects initial results in the first half of 2028, supporting potential approval by 2029.
